← Leaderboards
Cecile Tremblay
Centre Hospitalier De L'Universite De Montreal (University Of Montreal Hospital)
$4,232,447
Attributed
$4,232,447
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $829.3K · FY2016–25$1M$750K$500K$250K$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,232,447 · 1
By mechanism
R01$4,232,447 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Elderly”
- Charles A Coltman · Southwest Oncology Group$158,376,564
- Richard L Schilsky · University Of Chicago$122,071,723
- Michael W Weiner · Northern California Institute Res &Educ$99,760,701
- Monica M Bertagnolli · Strang Cancer Prevention Center$99,246,201
- Richard Mayeux · Columbia University Health Sciences$83,247,500
- Peter Gordon Gillespie · Oregon Health And Science University$80,983,248
Research focus
ElderlyImmune ActivationChronicCytokineFunctional DisorderHomeostasisCardiovascular DiseasesCellsCohort StudiesCoronary ArteryEventAntiretroviral TherapyAge RelatedHiv InfectionsArthritisCalciumAgingCd4 Positive T LymphocytesBlood VesselsCohortBiological MarkersComplexEpithelial CellsImmune System
Grant awards (9)
Role of IL-32 as a predictor and mediator of Premature Aging Phenotypes(PAP) in HIV infection.$829,283
R01 · FY2025 · AG · contact PI
Role of IL-32 as a predictor and mediator of Premature Aging Phenotypes(PAP) in HIV infection.$427,996
R01 · FY2024 · AG · contact PI
Role of IL-32 as a predictor and mediator of Premature Aging Phenotypes(PAP) in HIV infection.$433,719
R01 · FY2023 · AG · contact PI
Role of IL-32 as a predictor and mediator of Premature Aging Phenotypes(PAP) in HIV infection.$439,372
R01 · FY2022 · AG · contact PI
Exploring the role of IL-32 as a potential biomarker and therapeutic target in premature cardio-vascular diseases during HIV-infection.$438,200
R01 · FY2020 · AG · contact PI
Exploring the role of IL-32 as a potential biomarker and therapeutic target in premature cardio-vascular diseases during HIV-infection.$399,411
R01 · FY2019 · AG · contact PI
Exploring the role of IL-32 as a potential biomarker and therapeutic target in premature cardio-vascular diseases during HIV-infection.$434,974
R01 · FY2018 · AG · contact PI
Exploring the role of IL-32 as a potential biomarker and therapeutic target in premature cardio-vascular diseases during HIV-infection.$395,625
R01 · FY2017 · AG · contact PI
Exploring the role of IL-32 as a potential biomarker and therapeutic target in premature cardio-vascular diseases during HIV-infection.$433,867
R01 · FY2016 · AG · contact PI